165 related articles for article (PubMed ID: 29024842)
1. Peritoneal carcinomatosis-like implants of extramedullary hematopoiesis. An insolite occurrence during splenectomy for myelofibrosis.
Casaccia M; Fornaro R; Frascio M; Palombo D; Stabilini C; Firpo E; Gianetta E
Int J Surg Case Rep; 2017; 41():9-11. PubMed ID: 29024842
[TBL] [Abstract][Full Text] [Related]
2. Modern management of splenomegaly in patients with myelofibrosis.
Tremblay D; Schwartz M; Bakst R; Patel R; Schiano T; Kremyanskaya M; Hoffman R; Mascarenhas J
Ann Hematol; 2020 Jul; 99(7):1441-1451. PubMed ID: 32417942
[TBL] [Abstract][Full Text] [Related]
3. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
4. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
Mughal TI; Vaddi K; Sarlis NJ; Verstovsek S
Int J Gen Med; 2014; 7():89-101. PubMed ID: 24501543
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
6. SPLENECTOMY FOR MARKED SPLENOMEGALY DUE TO EXTRAMEDULLARY HEMATOPOIESIS.
SNYDER H
Med Rec Ann; 1964 Jan; 57():277-8. PubMed ID: 14115110
[No Abstract] [Full Text] [Related]
7. Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly.
Kawano N; Saito N; Yoshida S; Kitanaka A; Shide K; Marutsuka K; Ohshima K; Shimoda K
Tohoku J Exp Med; 2022 Feb; 256(2):119-125. PubMed ID: 35173090
[TBL] [Abstract][Full Text] [Related]
8. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
9. Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature.
Coltro G; Mannelli F; Vergoni F; Santi R; Massi D; Siliani LM; Marzullo A; Bonifacio S; Pelo E; Pacilli A; Paoli C; Franci A; Calabresi L; Bosi A; Vannucchi AM; Guglielmelli P
Clin Exp Med; 2020 May; 20(2):313-320. PubMed ID: 32065308
[TBL] [Abstract][Full Text] [Related]
10. How I treat symptomatic splenomegaly in patients with myelofibrosis.
Mesa RA
Blood; 2009 May; 113(22):5394-400. PubMed ID: 19332765
[TBL] [Abstract][Full Text] [Related]
11. Treatment and management of myelofibrosis in the era of JAK inhibitors.
Keohane C; Radia DH; Harrison CN
Biologics; 2013; 7():189-98. PubMed ID: 23990704
[TBL] [Abstract][Full Text] [Related]
12. Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications.
Malato A; Rossi E; Tiribelli M; Mendicino F; Pugliese N
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):588-595. PubMed ID: 32482540
[TBL] [Abstract][Full Text] [Related]
13. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562644
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic myelofibrosis accompanied by peritoneal extramedullary hematopoiesis presenting as refractory ascites in a dog.
Rautenbach Y; Goddard A; Clift SJ
Vet Clin Pathol; 2017 Mar; 46(1):46-53. PubMed ID: 27874969
[TBL] [Abstract][Full Text] [Related]
15. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt.
Mishchenko E; Tefferi A
Eur J Haematol; 2010 Sep; 85(3):192-9. PubMed ID: 20528907
[TBL] [Abstract][Full Text] [Related]
17. Ascites revealing peritoneal and hepatic extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia: case report and review of the literature.
Lioté F; Yeni P; Teillet-Thiebaud F; Barge J; Devars Du Mayne JF; Flamant Y; Molas G; Carbon C
Am J Med; 1991 Jan; 90(1):111-7. PubMed ID: 1986577
[TBL] [Abstract][Full Text] [Related]
18. [A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis].
Corella F; Barnadas MA; Bordes R; Curell R; Espinosa I; Vergara C; Alomar A
Actas Dermosifiliogr; 2008 May; 99(4):297-300. PubMed ID: 18394406
[TBL] [Abstract][Full Text] [Related]
19. Massive ascites caused by peritoneal extramedullary hematopoiesis as the initial manifestation of myelofibrosis.
Hung SC; Huang ML; Liu SM; Hsu HC
Am J Med Sci; 1999 Sep; 318(3):198-200. PubMed ID: 10487412
[TBL] [Abstract][Full Text] [Related]
20. Rapid Hepatomegaly From Ruxolitinib Discontinuation Syndrome.
van Rensburg RJ; Hale S; Calara A; Dabb K; Dandamudi U; Desai P
HCA Healthc J Med; 2023; 4(2):199-204. PubMed ID: 37424984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
